J&J Oncology Surge Confirms Base Case, But Valuation and Risks Cap Upside

What happened

J&J's Q1 oncology sales surged 17.8% year-over-year, led by Darzalex and new launches, aligning with the company's target of $50 billion in cancer revenue by 2030. This performance matches the base case in our master report, where ex-Stelara Innovative Medicine growth runs in the low double digits. However, the stock at $216.58 already prices in this success, trading at ~21x trailing earnings with limited margin of safety. Stelara erosion, talc litigation overhang, and rising net debt to $27.2 billion constrain upside despite strong operational execution. The near-term outlook is favorable, but the risk-reward is skewed to the downside given the lack of a clear catalyst to drive further multiple expansion.

Implication

J&J's oncology momentum supports mid-single-digit revenue growth, but current valuation and unresolved legal and pricing risks argue for patience. Attractive entry around $190, where risk-reward improves. For holders, consider trimming above $235 per our target. Reassess after Q2 results and talc Daubert rulings.

Thesis delta

The Q1 oncology growth confirms our base case but does not shift risk-reward. Stock remains a WAIT until a pullback or clearer legal outcomes provide a better entry. No change to $190 attractive entry and $235 trim level.